EVALUATION OF ANTI-INFLAMMATORY EFFECT OF PITAVASTATIN WITHMONOCYTE COUNT TO HDL CHOLESTEROL RATIO


Günay Ş. , Çalışkan S.

16 th International Congress of Update in Cardiology and Cardiovascular Surgery , İzmir, Turkey, 30 October - 01 November 2020, pp.715

  • Publication Type: Conference Paper / Summary Text
  • City: İzmir
  • Country: Turkey
  • Page Numbers: pp.715

Abstract

Background: Monocyte to HDL cholesterol ratio (MHR) was proposed as a novel inflammation marker. Some pleiotropic effects of statins are anti-inflammatory. Aims: To examine the effect of lipid-lowering therapy with pitavastatin on MHR in patients with coronary heart disease Study Design: Cross sectional study, Methods: A total of 150 patients were enrolled for this study. Hospital registries between October 2018 and April 2019 were reviewed retrospectively.Eligible patients were those who had both stable coronary artery disease and hypercholesterolemia of LDL>100 mg/dl and were started to be treated withpitavastatin 4 mg/day. Complete blood count values and lipid parameters before and after treatment were evaluated and monocyte count to high densitylipoprotein ratios were calculated before and after treatment. Results: Pitavastatin 4 mg/day was administered for 1-7 months. The difference between the mean total cholesterol, triglyceride, LDL-C levels before andafter treatment was statistically significant ( p<0.001, p=0.020, p<0.001, respectively) ). Monocyte/HDL ratio was similar between groups Conclusion: In our study, it was concluded that pitavastatin improved serum lipid leves but did not decrease MHR.